| 摘要 |
1. A method for preventing or for treating chronic pain comprising administering to a patient in need of treatment an effective amount of a synergistic combination of a NK1 receptor antagonist and a GABA analog. 2. A method of claim 1, wherein the ratio of the GABA analog relative to the NK1 receptor antagonist is from 50:1 to 1:1 expressed as parts by weight. 3. A method of claim 1, wherein the ratio of the GABA analog relative to the NK1 receptor antagonist is 20:1 expressed as parts by weight. 4. A method according to claim 1, wherein the NK1 receptor antagonist is [2 (1H-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester[R-(R*,S*)]. 5. A method according to claim 1, wherein the GABA analog is gabapentin. 6. A method according to claim 1, wherein the GABA analog is pregabalin. 7. A method according to claim 1 employing [2-(1H-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)] and gabapentin. 8. A method according to claim 1 employing [2-(1H-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)] and pregabalin. 9. A method according to claim 1, wherein the condition treated is selected from causalgia, neuropathic pain, diabetic neuropathy, post-surgery or traumatic neuropathy, postherpetic neuralgia, peripheral neuropathy, entrapment neuropathy, phantom limb and stump pain, neuropathy caused by alcohol abuse, HIV infection, multiple sclerosis, hypothyroidism or anticancer chemotherapy. 10. A pharmaceutical composition comprising synergistic effective amounts of a NK1 receptor antagonist and a GABA analog. 11. A composition of claim, 10 wherein the ratio of the GABA analog relative to the NK1 receptor antagonist is from 50: 1 to 1:1 expressed as parts by weight. 12. A composition of claim 10, wherein the ratio of the GABA analog relative to the NK1 receptor antagonist is 20:1 expressed as parts by weight. 13. A composition of claim 10, wherein the NK1 receptor antagonist is [2-(1H indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester[R-(R*,S*)]. 14. A composition of claim 10, wherein the GABA analog is gabapentin. 15. A composition of claim 10, wherein the GABA analog is pregabalin. 16. A composition of claim 10 employing [2-(1H-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)] and gabapentin. 17. A composition of claim 1 employing [2-1H-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)] and pregabalin. 18. The use of a composition comprising synergistic effective amounts of a NK1 receptor antagonist and a GABA analog, or pharmaceutically acceptable salts thereof, for the preparation of a medicament useful for preventing or treating chronic pain.
|
